Credit Suisse (SIX:CSGN) analyst Matt Miksic reiterated a Buy rating on Medtronic (NYSE:MDT) on Thursday, setting a price target of $117, which is approximately 27.59% above the present share price of $91.7.
Miksic expects Medtronic to post earnings per share (EPS) of $0.48 for the third quarter of 2020.
The current consensus among 22 TipRanks analysts is for a Strong Buy rating of shares in Medtronic, with an average price target of $112.23.
The analysts price targets range from a high of $130 to a low of $92.
In its latest earnings report, released on 04/30/2020, the company reported a quarterly revenue of $6 billion and a net profit of $384 million. The company's market cap is $123.83 billion.
According to TipRanks.com, Credit Suisse analyst Matt Miksic is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 9.4% and a 62.98% success rate.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.